106 results about "Myoma" patented technology

The invention relates to the technical field of focus positioning, in particular to a hysteromyoma focus accurate positioning method combining image analysis and data fusion, which comprises the following steps: acquiring multi-modal uterus image data, and carrying out artifact suppression and spatial registration on an original image; performing three-dimensional reconstruction on the preprocessed multi-modal image data set to generate a three-dimensional uterus model comprising anatomical structure features; lesion feature segmentation is carried out in the three-dimensional uterus model, and morphological parameters and textural features of a myoma lesion are extracted; carrying out hemodynamic analysis to obtain blood perfusion parameters and blood vessel distribution characteristics of the focus area; the blood perfusion parameters and the blood vessel distribution characteristics are fused, the three-dimensional uterus model is combined, and a focus biomechanical characteristic distribution diagram is constructed; and generating a real-time navigation path according to the biomechanical characteristic distribution diagram, and outputting a positioning report. According to the method, personalized ablation energy suggestions are made, the ablation treatment efficiency and success rate are effectively improved, the ablation energy is dynamically adjusted, and the treatment efficiency and safety are ensured.

The invention belongs to the field of biological pharmacy, and provides keratin YK93-4, a coding nucleic acid molecule thereof, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or genome integrated with the nucleic acid molecule, and a preparation method and a pharmaceutical composition of the keratin YK93-4. The invention also provides application of the keratin YK93-4 and related products thereof in preparation of medicines for treating lung cancer, lymphoma, breast cancer, melanoma, hysteromyoma, benign prostatic hyperplasia and the like.

This invention belongs to the field of biopharmaceuticals and provides a keratin YK93-6, its encoding nucleic acid molecule, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or whose genome integrates the nucleic acid molecule, as well as a preparation method and a pharmaceutical composition thereof. It also provides the application of the above-mentioned keratin YK93-6 and other products in the preparation of drugs for treating benign prostatic hyperplasia, lymphoma, melanoma, analgesia, lactation, breast cancer, lung cancer, uterine fibroids, coagulation, etc.

The invention belongs to the field of biological pharmacy, and provides keratin YK93-5, a coding nucleic acid molecule thereof, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or genome integrated with the nucleic acid molecule, and a preparation method and a pharmaceutical composition of the keratin YK93-5. The invention also provides application of the keratin YK93-5 and other products in preparation of drugs for treating lung cancer, lymphoma, breast cancer, melanoma, hysteromyoma, prostatic hyperplasia and the like.

This invention belongs to the field of biopharmaceuticals and provides a keratin YK93-8, its encoding nucleic acid molecule, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or whose genome integrates the nucleic acid molecule, as well as a preparation method and a pharmaceutical composition thereof. It also provides the application of the above-mentioned keratin YK93-8 and other products in the preparation of drugs for treating benign prostatic hyperplasia, lymphoma, melanoma, breast cancer, lung cancer, analgesia, lactation, uterine fibroids, coagulation, etc.

The invention discloses a human-derived hysteromyoma targeting peptide and application thereof, the sequence of the targeting peptide is selected from SEQ ID NO: 1 to SEQ ID NO: 5, and the SEQ ID NO: 1 (VN12) is the most preferable. The fusion protein is obtained by screening through a phage display technology, and has high hysteromyoma targeting specificity and low immunogenicity. The targeting peptide can be coupled with nuclide or fluorescent dye, and is used for accurate PET imaging, fluorescent diagnosis and intraoperative navigation of hysteromyoma. Experiments prove that the molecular marker is specifically enriched in tumor tissues (the tumor / muscle ratio is 60), the biological safety is good, the problems of insufficient diagnosis sensitivity and large treatment wound in the prior art are solved, and the molecular marker has a great application prospect in diagnosis and treatment of hysteromyoma.

The invention relates to the technical field of hysteroscope resectoscopes, and discloses a hysteroscope resectoscope capable of preventing uterine perforation and a using method thereof.The hysteroscope resectoscope comprises a hysteroscope body and a plurality of ultrasonic ranging modules, a camera is arranged at the far end of the hysteroscope body and faces the resection position, the ultrasonic ranging modules are arranged at the far end, and the ultrasonic ranging modules are arranged at the far end of the hysteroscope body and face the resection position. The ultrasonic ranging modules face the electric resection part and are used for measuring the thickness of the uterus wall of the electric resection part. According to the hysteroscope, the ultrasonic ranging modules are arranged at the far end of the hysteroscope body to measure the thickness of the uterus wall of the electric resection part, the situation that when an electric resection operation of uterine submucosal myoma or endometrial polyp is carried out, due to the fact that the thickness of the uterus wall cannot be accurately evaluated, uterus perforation is accidentally caused is avoided, the safety and accuracy of the operation are improved, and the operation efficiency is improved. Complications are reduced, and the fertility of a patient is protected.

The invention discloses a uterine fibroid recognition method based on artificial intelligence. The method comprises the following steps of S1, collecting medical image data of a tested person; s2, preprocessing the medical image data; s3, inputting the preprocessed data into a uterine fibroid deep learning model based on artificial intelligence to extract uterine fibroid features; wherein the deep learning model comprises a feature extraction layer, the feature extraction layer adopts a structure comprising a convolutional layer and jump connection, and the jump connection can select different processing modes according to an obtained input feature map and channel number so as to facilitate information transmission and gradient propagation; and S4, inputting the hysteromyoma features into a classification layer to obtain a hysteromyoma recognition result. According to the invention, aiming at the magnetic resonance medical image, a data processing and deep learning method is improved, and the accuracy and reliability of hysteromyoma identification are further improved.

The invention provides a 3D U-Net-based hysteromyoma intelligent measurement and evaluation system, and the system comprises an intelligent recognition module which is used for constructing a 3D U-Net network model, inputting a real-time image into the 3D U-Net network model for myoma boundary recognition, and judging whether a patient suffers from hysteromyoma or not; the three-dimensional reconstruction module is used for performing three-dimensional reconstruction on the real-time image when the judgment result is that the patient suffers from the hysteromyoma; the growth prediction module is used for performing uterine fibroid growth prediction according to the three-dimensional reconstruction result and outputting a growth prediction result; and the three-dimensional relationship between the myoma and the uterine muscular layer, the blood vessel and other organs can be observed more clearly, so that a more accurate basis is provided for formulating a personalized treatment scheme.

The invention discloses an application of a DHA-RXR-PPAR signal channel in promotion of postoperative recovery of hysteromyoma after HIFU (high intensity focused ultrasound). Clinical sample metabolic spectrum analysis and in-vitro cell function experiments are combined, and research proves that the differential metabolite DHA drives macrophage metabolism reprogramming through an RXR-PPAR signal axis, so that the macrophage is promoted to be transformed into an anti-inflammatory and phagocytosis-promoting repair phenotype, the absorption and repair process of the HIFU postoperative hysteromyoma is accelerated, and the treatment effect of the HIFU postoperative hysteromyoma is improved. A new intervention target spot (RXR-PPAR gamma axis) and a new potential medicine are provided for HIFU (high intensity focused ultrasound) postoperative rehabilitation.

The sustained-release formulation of this invention, with its increased initial release, exhibits a rapid release effect within 24 hours after administration, followed by a sustained-release effect, thus simultaneously achieving both prolonged efficacy and rapid initial release. The sustained-release formulation of this invention, containing microspheres of leuprorelin, possesses excellent bioavailability and has been proven safe in humans; therefore, it can be effectively and safely used to treat various luteinizing hormone-releasing hormone-related diseases such as endometriosis, uterine fibroids, prostate cancer, premenopausal breast cancer, and central precocious puberty.

The invention belongs to the field of medical instruments, and particularly discloses a gradient dentition-based hysteromyoma rotary cutter which comprises a rotary cutter bar, the rotary cutter bar is of a hollow tubular structure, a conveying cavity is formed in the rotary cutter bar in a penetrating mode in the axis direction of the rotary cutter bar, a gradient dentition structure is arranged on the inner wall of the front end of the conveying cavity, and the gradient dentition structure is arranged in the axis direction of the conveying cavity; the pull rod is arranged to pull the hysteromyoma slice to promote the hysteromyoma slice to be conveyed to the rear end of the conveying cavity when the rotary cutter bar rotates; the rotary cutter head is fixedly connected to the front end of the rotary cutter bar and is used for cutting hysteromyoma; and a rotary cutting driving device is arranged in the operating handle, is in transmission connection with the rear end of the rotary cutter bar, and is configured to drive the rotary cutter bar to rotate by taking the axis of the rotary cutter bar as a rotating shaft. By means of the structural design, the rotary cutter can pull cut hysteromyoma slices to be conveyed backwards, continuity and high efficiency of an operation are ensured, and meanwhile diffusion of tissue fragments in an operation area is prevented.

The utility model provides a pair of separating forceps for hysteromyoma surgery, which relates to the technical field of medical instruments and comprises two forceps arms, the two forceps arms are rotationally connected through a rotating shaft, one ends of the two forceps arms are respectively provided with a forceps head, the other ends of the two forceps arms are respectively provided with forceps handles, and one ends of the two forceps handles are respectively and fixedly connected with finger rings. The required forceps heads can be replaced according to actual operation requirements through the dismounting and mounting assembly, the preoperative preparation time before an operation is shortened, one set of forceps arms can use various forceps heads, the cost is reduced, and the forceps heads can be independently replaced when a single part is abraded and the like, secondly, the working angles of the forceps handles can be adjusted according to the operation conditions through the bending assembly, and the working efficiency is improved. By means of the technical scheme, the handle can be better attached to an operation area and held in a more comfortable posture, the accuracy of force application and operation is improved, and muscular tension and hand fatigue caused by long-time operation can be reduced.

The invention belongs to the field of biological pharmacy, and provides keratin YK93-2, a coding nucleic acid molecule thereof, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or genome integrated with the nucleic acid molecule, and a preparation method and a pharmaceutical composition of the keratin YK93-2. The invention also provides application of the keratin YK93-2 and other products in preparation of drugs for treating lung cancer, lymphoma, breast cancer, melanoma, hysteromyoma, prostatic hyperplasia and the like.

The invention discloses a method for classifying hysteromyoma and hysterosarcoma by using MRI (Magnetic Resonance Imaging) imageomics, which comprises the following steps of: acquiring MRI original image data of two types of patients with lesions through a three-dimensional image processing workstation, and extracting feature data; inputting the image data into an MRI image perception graph convolutional network, dynamically adjusting and extracting features through a multi-scale convolution kernel, and generating an initial image feature graph; inputting the initial feature map into a generative adversarial feature unwrapping network, and separating calibration features and interference features through adversarial training of a generator and a discriminator; the calibration features are input into a multi-instance learning attention model, lesion area feature representation is enhanced through a weight distribution mechanism, and weighted features are obtained; and constructing a lesion classification feature set in combination with MRI image omics features, and outputting a classification result by a classifier according to the optimized feature set. According to the method, the feature quality is cooperatively improved through a multi-link technology, the classification accuracy and objectivity are guaranteed, subjective interference is reduced, different MRI image characteristics are adapted, and clinical precise classification requirements can be met.

The utility model relates to the technical field of medical equipment, in particular to a disposable multi-specification uterus lifting cup which comprises a uterus lifting frame, a multi-stage uterus lifting cup, a uterus lifting rod, a myoma drill and a guide rod. A first operation screw is arranged on the side portion of the uterus lifting frame, and a first limiting insertion hole is formed in the uterus lifting frame. The multi-stage uterus lifting cup is mounted at one end, far away from the first operation screw, of the uterus lifting frame; the uterus lifting rod is installed in the first limiting penetrating hole, a second limiting penetrating hole is formed in the uterus lifting rod, and a second operation screw is arranged on the side portion of the uterus lifting rod. The myoma drill is installed at the end, away from the second operation screw, of the uterus lifting rod. The guide rod is mounted in the second limiting insertion hole; the multi-stage uterus lifting cup comprises an expansion adjusting seat installed on the uterus lifting frame, the abutting end of the expansion adjusting seat can be expanded and adjusted, an expansion adjusting ring is installed in the expansion adjusting seat, and the operation safety and the overall efficiency can be effectively improved.

The present invention relates to a nitrogen-containing heteropolycyclic derivative modulator, a preparation method therefor and the use thereof. In particular, the present invention relates to a compound represented by general formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and the use thereof as a modulator in the preparation of drugs for treating menopausal syndrome, polycystic ovarian syndrome, uterine fibroids, schizophrenia, irritable bowel syndrome, vasomotor symptoms, breast cancer and related disorders thereof, wherein each substituent in general formula (I) is the same as defined in the description.

The present invention relates to the method of treating heavy menstrual bleeding in a subject with or without uterine fibroids and in need of treatment by administering an effective amount of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid or a pharmaceutically acceptable salt thereof, in combination with estrogens and progestogens.

The utility model discloses a hysteromyoma pulverizator, relates to the field of medical instruments, and provides a hysteromyoma pulverizator of which a structure in contact with tissue of a patient can be conveniently detached to be cleaned and disinfected. The hysteromyoma crusher comprises a shell, a driving device, a crushing sleeve, a crushing shaft and a suction structure, the machine shell comprises a main sleeve. The driving device comprises a driving shaft and a motor, and the driving shaft and the main sleeve are coaxially arranged and installed in the main sleeve; the crushing sleeve is located in front of the main sleeve, and the crushing sleeve and the main sleeve are coaxially arranged and detachably connected; the crushing shaft is located in the crushing sleeve and coaxially arranged with the crushing sleeve, the crushing shaft comprises a shaft body, a crushing head and a sealing sleeve, the shaft body is detachably connected with the driving shaft, the crushing head is connected with the front end of the shaft body, the sealing sleeve is arranged on the shaft body in a sleeving mode, and the sealing sleeve is matched with the crushing sleeve; a suction connector located in front of the sealing sleeve and close to the sealing sleeve is arranged on the lower portion of the smashing sleeve. The suction structure is connected with the suction connector.

The present invention relates to the technical field of medical devices, and provides a uterine fibroid steam ablation puncture handle device, comprising a shell, a puncture catheter assembly, a sliding assembly and an operating mechanism, wherein a stop structure is provided in the shell, and the puncture catheter assembly includes a puncture needle; the sliding assembly is provided in the shell, the sliding assembly is fixedly connected to the puncture needle, and a locking structure is movably provided on the sliding assembly; the operating mechanism is provided in the shell, the operating mechanism slides to drive the sliding assembly, the operating mechanism is transmission-connected to the locking structure, and the operating mechanism has a first state and a second state; in the first state, the locking structure contacts and cooperates with the stop structure to limit the sliding of the sliding assembly; in the second state, the operating member drives the locking structure to move to separate from the stop structure to release the restriction on the sliding of the sliding assembly; after the sliding assembly slides to the target position, the operating mechanism resets to the first state, and can achieve locking, which is beneficial to avoid changes in the expected treatment area of ​​ablation and prevent damage to surrounding tissues.

Embodiments of the present application disclose an ultrasound image registration method, device and electronic equipment, the method comprising the following steps: acquiring an abdominal ultrasound image of a patient as a floating image, and extracting a uterine fibroid contour in the floating image based on a trained network model; acquiring a corresponding abdominal gray-scale ultrasound as a reference image, and labeling an upper boundary of the uterine fibroid to obtain an incomplete contour; fitting the obtained complete and incomplete uterine fibroid contours into regular geometric contours; describing the regular geometric contours using a point set shape description method, and matching regular elliptical contours in the regular geometric contours to regular elliptical arc contours according to a shape difference matching rule; and describing the initial complete and incomplete uterine fibroid contours using the point set shape description method, matching the point sets of the initial complete and incomplete uterine fibroid contours according to the shape difference, and obtaining a transformation matrix to perform fine registration.

The present application relates to the technical field of biological medicine, and more particularly to the application of aspirin in treating uterine fibroid degeneration during pregnancy. The application of aspirin in preparing a drug or health product for treating and / or preventing uterine fibroid degeneration during pregnancy. The dosage of aspirin in the drug is 100 mg per day. The present application uses aspirin to treat and / or prevent uterine fibroid degeneration during pregnancy, and the drug is widely used during pregnancy. It has been basically confirmed that the drug can be used for a long time in pregnant women, and the drug has the functions of relieving pain, improving blood flow, not being limited to gestational weeks, and being able to be used for a long time. The application of the drug can reduce the hospitalization rate of patients. For high-risk groups with pregnancy combined with uterine fibroid degeneration, the drug can be used as a preventive drug to reduce the occurrence of uterine fibroid degeneration. The treatment of the drug can significantly reduce the patients who change to surgical treatment due to the failure of conservative treatment of myoma degeneration.

The invention provides a hysteromyoma composite ablatometer for high-frequency focused ultrasound combined with photodynamic therapy, and relates to the technical field of hysteromyoma treatment equipment.The hysteromyoma composite ablatometer comprises a host, a display module and a diagnosis and treatment bed, an adjustable cantilever is installed on one side of the diagnosis and treatment bed, and a treatment probe is arranged at the end of the adjustable cantilever; a contact end is installed at the opening position of the lower end of the treatment probe, an ultrasonic treatment control module and an optical treatment control module are arranged on the upper side of the contact end in the treatment probe, and a terminal cooling assembly used for cooling the contact end, the optical treatment control module and the ultrasonic treatment control module is installed outside the treatment probe. The ultrasonic imaging control module is arranged on the outer surface of the treatment probe, the cooling assembly can generate high-speed airflow and guide the airflow into the cooling channel, the bottom sheet and the top sheet are cooled through the airflow, temperature rise of the contact end when the contact end makes contact with the skin part of a patient is avoided, and the phenomenon that the skin is injured in the using process is avoided.

This application relates to the field of automated gynecological disease technology, specifically a method and system for predicting the risk of uterine fibroids. By combining multiple sets of clinical indicators and multiple sets of imaging feature data, this application can effectively assess and predict the preoperative risk of uterine fibroids, especially for high-intensity focused ultrasound ablation. This scoring data provides a more intuitive determination of preoperative risk, thereby achieving an accurate assessment of the preoperative risk of uterine fibroids. Compared to existing technologies that rely solely on physician clinical experience, this application combines imaging feature data with clinical indicators, resulting in a more accurate assessment.

The application discloses a uterus tumor differential diagnosis method and system based on multi-parameter MRI imaging and belongs to the technical field of medical image processing and artificial intelligence diagnosis. The method aims at the problems existing in the current uterus tumor MRI diagnosis, such as strong subjective dependence, insufficient utilization of multi-parameter information, unreasonable feature screening and model construction. The method comprises the following steps: collecting T1WI, T2WI, T2 fat suppression sequence and DWI multi-parameter images; after format standardization, deartifacting and Z-score normalization, a model combining U-Net and attention mechanism is used to realize automatic segmentation of the lesions; multi-dimensional features are extracted and the optimal subset is screened by ANOVA filtering-RFE-SVM packaging method; a stacking integrated model is constructed for training, and the output includes the differential results and confidence of ordinary uterine fibroids, special type uterine fibroids and uterine sarcoma; the application integrates multi-parameter complementary information, improves the segmentation efficiency and feature quality, has strong model generalization ability and accurate diagnosis, is suitable for the actual situation of the scarcity of uterine sarcoma cases, and provides an objective diagnosis tool for clinical use.

The present disclosure provides a myoma biological tissue segmentation method and an electronic device. The method comprises: performing spatial conversion and channel feature extraction on each first feature map obtained by performing multiple feature extractions on a medical image of a myoma biological tissue based on a spatial channel attention mechanism to obtain each second feature map; performing channel compression and feature extraction at least once on each up-sampling feature map obtained by up-sampling each second feature map to obtain a third feature map, wherein the same up-sampling feature map has the same number of times of channel compression and feature extraction, different up-sampling feature maps have different numbers of times of channel compression and feature extraction, any up-sampling feature map first performs channel compression once and then performs feature extraction once, and the image of the latter channel compression is the image obtained by fusing the feature map obtained by the former feature extraction and the up-sampling feature map; and obtaining the myoma biological tissue by using the third feature map and a fourth feature map obtained based on the second feature map. The accuracy of segmenting the myoma biological tissue is improved.

1. The name of this design product: Human magnetic induction uterine fibroid risk assessment instrument. 2. Purpose of this design product: This design product is an instrument used to assess the risk of uterine fibroids. 3. The key point of the design of this product lies in its shape. 4. The picture or photo that best illustrates the design points: Stereoscopic drawing 1.

The invention relates to the technical field of disinfection devices, in particular to a disinfection device for hysteromyoma dissection surgical instruments, which comprises a rack, a conveyor belt rotationally arranged on the rack and used for conveying surgical instruments, a disinfection box body fixed on the rack, an atomization box fixed on the inner side of the disinfection box body, and a pump body and a liquid storage tank fixed on the disinfection box body, a water inlet of the pump body is communicated with the liquid storage tank through a liquid inlet pipe, a plurality of atomizing nozzles for atomizing and spraying disinfectant are fixedly mounted on the inner side of the atomizing box, and a water outlet of the pump body is communicated with the atomizing nozzles through a liquid outlet pipe; the pump body comprises a main shaft with the output end connected with the impeller, and fan blades used for enhancing atomization and diffusion of sprayed disinfectant and air-drying the surgical instruments can be fixed to the main shaft, the surgical instruments used in the hysteromyoma dissection operation process can be rapidly disinfected, the disinfection effect is good, the sterility of reuse of the surgical instruments is guaranteed, and the service life of the surgical instruments is prolonged. Continuous use of surgical instruments is facilitated, and continuous operation is facilitated.

The invention discloses a hysteromyoma or uterus body rotary cutting pulverizator, and relates to the technical field of pulverizators. The hysteromyoma or uterus body rotary cutting pulverizator comprises a handle and a scabbard which are arranged on a pulverizator body, a knife tube is inserted into the scabbard, a pulverizing knife is arranged at the end of the knife tube, the knife tube is inserted into the scabbard, the head of the scabbard is sleeved with a pulverizing bag, the side wall of the knife tube is fixedly sleeved with an L-shaped plate, and the side wall of the L-shaped plate is fixedly sleeved with the pulverizing bag. The L-shaped plate is detachably connected with the side wall of the handle through a mounting mechanism, a movable pipe is inserted into the knife pipe, and a fixing rod is inserted into the movable pipe. According to the hysteromyoma or uterine body rotary-cut crusher, during rotary-cut crushing, the crushing bag can be prevented from being damaged, the crusher is safer and more reliable, meanwhile, the hysteromyoma or uterine body can be pushed to abut against the crushing knife, automatic air blowing cleaning can be conducted on the crushing knife, and the rotary-cut crushing efficiency and effect of the crushing knife are guaranteed.

The invention discloses a secondary cesarean delivery postpartum hemorrhage risk early warning model, and relates to the technical field of gynaecology and obstetrics medical treatment. The construction method of the early warning model comprises the following steps: data collection: collecting clinical data of a puerpera in secondary cesarean section, including basic and historical information, information of the gestation period, information of the delivery period of the gestation period and an outcome variable; single factor analysis: screening significant factors of an assisted reproductive technology, a pre-pregnancy body mass index, a pre-antenatal body mass index, pregnancy and birth times, previous cesarean birth times, the number of fetuses, gestational week termination, combined hypertension, combined hysteromyoma, a placenta and uterus relationship, fetal prolapse and uterus height. According to the method, based on large sample data and Logistic regression analysis, the gestational week of gestation termination is screened out, three independent risk factors of hysteromyoma and the relationship between the placenta and the uterus are combined, and model construction has statistical significance; risk scores are quantified through column diagram design, abstract risks are converted into visual values, and the clinical decision-making efficiency is improved.